Companies: 10,795·Total market cap: $144.5T
Relay Therapeutics, Inc.

Relay Therapeutics, Inc.

RLAYNASDAQHealthcare● Active
$13.84
+$0.32(+2.40%)
Market Cap$2.4B
P/E Ratio
52W High$17.47
52W Low$2.98

Relay Therapeutics, Inc. (RLAY) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

rlay · stock forecast · 15 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 15 Wall Street analysts in the past 3 months

SellBuy

Buy

15 analysts

consensus

Rating Breakdown

Strong Buy
1
Buy
14
Hold
0
Sell
0
Strong Sell
0
Total: 15 · Buy rate: 100.0%

12-Month Price Target

High

$28.00

Consensus

$24.00

+73.2% upside

Low

$18.00

Median: $26 · Last Close: $13.86

The Relay Therapeutics, Inc. (RLAY) analyst consensus is Buy, based on ratings from 15 Wall Street analysts over the past 3 months. The average 12-month RLAY price target is $24.00, representing +73.2% upside from the current price of $13.86.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $24 (73.2%)

Consensus Target

$24.00

73.2% upside

High Target

$28

102.0%

Low Target

$18

29.9%

Current Price

$13.86

as of today

Based on analyst price targets, the RLAY stock price prediction for the next 12 months ranges from $18 to $28. The consensus RLAY price forecast of $24.00 implies 73.2% upside from the current price of $13.86.

Short-Term Price Prediction

Bull

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$14.555.00%

1-day model range: $14.43–$14.67. Peak: $14.67 (+5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$15+4.9%
2028$15+8.0%
2029$15+9.9%
2030$15+11.0%
2031+11.7%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

57%7%36%
8Buy
1Neutral
5Sell
RSI (14)61.7Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · RLAY · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$14.58SELL
MA 10$14.37SELL
MA 20$13.60BUY
MA 50$13.67BUY
MA 100$11.36BUY
MA 200$8.87BUY
Current $RLAY · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$14.17SELL
EMA 10$14.14SELL
EMA 20$13.89SELL
EMA 50$13.16BUY
EMA 100$11.74BUY
EMA 200$9.72BUY
Current $RLAY · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
HC Wainwright & Co.2026-05-26
Maintains
BuyBuy
Guggenheim2026-05-26
Maintains
BuyBuy
Citizens2026-05-20
Maintains
Market OutperformMarket Outperform
Barclays2026-05-20
Maintains
OverweightOverweight
Raymond James2026-05-19
Maintains
Strong BuyStrong Buy
HC Wainwright & Co.2026-04-29
Maintains
BuyBuy
Citizens2026-04-28
Maintains
Market OutperformMarket Outperform
Goldman Sachs2026-04-28
Maintains
BuyBuy
Oppenheimer2026-04-28
Maintains
OutperformOutperform
Wells Fargo2026-04-28
Maintains
OverweightOverweight

Wall Street analysts have recently issued updated ratings on Relay Therapeutics, Inc. (RLAY) stock. Of the recent 86 rating actions, 6 were upgrades and 1 were downgrades. 15 analysts currently cover RLAY.

Analyst Recommendation Trends

Buy ratings15↑ +4
Hold ratings00
Sell ratings00

RLAY analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 5 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$12M

↓ 78.5% YoY

Revenue Next Year

$20M

↑ 65.2% YoY

EPS This Year

$-1.57

EPS Next Year

$-1.62

↑ 3.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast RLAY EPS of $-1.57 for the current fiscal year, based on estimates from 8 analysts. The RLAY revenue forecast is $12M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The RLAY stock forecast is supported by two independent data sources: analyst consensus ratings from 15 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RLAY price target is $24.00 (+73.2% upside), with an analyst consensus of Buy.

The RLAY short-term stock prediction for tomorrow is $14.55 (+5.00%). The RLAY stock price prediction for 2027 estimates an average of $15. The RLAY stock prediction for 2030 projects a range of $14–$17.

Relay Therapeutics, Inc. trades on NASDAQ under the ticker RLAY. The RLAY stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

RLAY forecast · 8 questions

According to 15 Wall Street analysts, the average 12-month RLAY price target is $24.00, with a high forecast of $28.00 and a low of $18.00. The median price target is shown in the chart above when available. This implies +73.2% potential upside from the current price of $13.86.

RLAY price targetWhat is RLAY price targetRLAY analyst price targetRLAY 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.